公开(公告)号：US08126958B2

公开(公告)日：2012-02-28

申请号：US13189524

申请日：2011-07-24

Applicant: Naresh Kumar ,  Robert Perry

Inventor： Naresh Kumar ,  Robert Perry

IPC: G06F15/16 ,  G06F15/173 ,  H04N7/16 ,  H04N7/173

CPC classification number: H04L12/14 ,  G06F11/2033 ,  G06F11/2038 ,  G06F11/2041 ,  H04L12/1403 ,  H04L69/40 ,  H04M15/70 ,  H04M15/74 ,  H04M2215/70 ,  H04M2215/709

Abstract: A determination is made whether a first application server of a group of N application servers, N being at least two, is a coordinator of the group. Responsive to determining that the first application server is the coordinator of the group, a connection to a billing system is established, via a terminal server, by the first application server. A determination is made whether a second application server of the group of N application servers is the coordinator of the group. Responsive to determining that the second application server is not the coordinator of the group, a periodic check is made whether the second application server of the group of N application servers is the coordinator of the group. The second application server may later be determined to be the coordinator of the group, when the first server experiences difficulty. Once it is determined that the second application server now is the coordinator of the group, a connection is established to the billing system, via the terminal server, by the second application server.

Abstract translation: 确定一组N个应用服务器的第一应用服务器是否为该组的协调器，N至少为两个。 响应于确定第一应用服务器是该组的协调器，通过终端服务器由第一应用服务器建立与计费系统的连接。 确定N个应用服务器组的第二应用服务器是否是该组的协调器。 响应于确定第二应用服务器不是组的协调器，定期检查N个应用服务器组中的第二应用服务器是否是该组的协调器。 当第一服务器遇到困难时，可以将第二应用服务器确定为该组的协调器。 一旦确定第二应用服务器现在是组的协调器，则通过第二应用服务器经由终端服务器向计费系统建立连接。

公开(公告)号：US20110046722A1

公开(公告)日：2011-02-24

申请号：US12528208

申请日：2008-02-29

Applicant: Andrew Heaton ,  Naresh Kumar ,  Catherine Walker

Inventor： Andrew Heaton ,  Naresh Kumar ,  Catherine Walker

IPC: A61F2/82 ,  C07D498/04 ,  A61K31/5365 ,  A61P9/00 ,  A61P29/00 ,  A61P39/06

CPC classification number: C07D498/04

Abstract: The invention provides oxazinyl isoflavonoid compounds and compositions containing same, methods for their preparation and their use as therapeutic agents particularly as cardioprotective, anti-inflammatory, anti-oxidant and chemotherapeutic agents.

Abstract translation: 本发明提供了恶嗪基异黄酮化合物和含有其的组合物，其制备方法及其作为治疗剂的用途，特别是作为心脏保护剂，抗炎剂，抗氧化剂和化学治疗剂。

公开(公告)号：US20100144801A1

公开(公告)日：2010-06-10

申请号：US12443838

申请日：2007-10-02

Applicant: Naresh Kumar ,  Jaskiran Kaur ,  Abhijit Ray ,  Suman Gupta ,  Shivani Malhotra ,  Rajkumar Shirumalla

Inventor： Naresh Kumar ,  Jaskiran Kaur ,  Abhijit Ray ,  Suman Gupta ,  Shivani Malhotra ,  Rajkumar Shirumalla

IPC: A61K31/44 ,  C07D213/55 ,  C07D233/54 ,  A61K31/4164 ,  A61P11/00 ,  A61P13/00 ,  A61P1/00 ,  A61P3/00

CPC classification number: C07D233/64 ,  C07D211/70 ,  C07D213/30

Abstract: The present invention generally relates to muscarinic receptor antagonists of formula I, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. Formula (I) wherein Het: is heterocyclyl or heteroaryl X: O, S or NR1 and the other substituents are defined as in the claims.

Abstract translation: 本发明一般涉及式I的毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病，以及其它用途。 本发明还涉及制备所公开的化合物的方法，含有所公开的化合物的药物组合物，以及用于治疗通过毒蕈碱受体介导的疾病的方法。 式（I）其中Het：是杂环基或杂芳基X：O，S或NR1，其它取代基如权利要求中所定义。

公开(公告)号：US20100035948A1

公开(公告)日：2010-02-11

申请号：US12311473

申请日：2007-10-08

Applicant: Naresh Kumar ,  George Iskander

Inventor： Naresh Kumar ,  George Iskander

IPC: A61K31/42 ,  C07D307/02 ,  A61K31/341 ,  C07D409/02 ,  A61K31/381 ,  C07D261/00 ,  C07D231/10 ,  A61K31/415 ,  C07D207/18 ,  A61K31/40 ,  A61P31/04 ,  A61P31/10 ,  A61P33/02 ,  A01N43/08 ,  A01N43/10 ,  A01N43/80 ,  A01N43/56 ,  A01N43/36

CPC classification number: C07D307/58 ,  C07D207/38 ,  C07D405/04 ,  C07D409/04 ,  C07D409/06

Abstract: The present invention provides a compound of formula I and a compound of formula II, methods of use and formulations thereof.

Abstract translation: 本发明提供式I化合物和式II化合物，其用途及其制剂。

公开(公告)号：US20090131410A1

公开(公告)日：2009-05-21

申请号：US12089150

申请日：2006-10-05

Applicant: Naresh Kumar ,  Kirandeep Kaur ,  Suman Gupta ,  Anita Chugh ,  Mohammad Salman ,  Raj Kumar Shirumalla ,  Shivani Malhotra

Inventor： Naresh Kumar ,  Kirandeep Kaur ,  Suman Gupta ,  Anita Chugh ,  Mohammad Salman ,  Raj Kumar Shirumalla ,  Shivani Malhotra

IPC: A61K31/55 ,  C07D223/14 ,  A61P3/10

CPC classification number: C07D221/24 ,  C07D405/12 ,  C07D409/12

Abstract: Provided are muscarinic receptor antagonists, which can be useful in treating various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Also provided are processes for preparing compounds described herein, pharmaceutical compositions thereof, and methods for treating diseases mediated through muscarinic receptors.

Abstract translation: 提供毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，尿和胃肠道系统的各种疾病。 还提供了用于制备本文所述的化合物的方法，其药物组合物，以及用于治疗通过毒蕈碱受体介导的疾病的方法。

公开(公告)号：US20090105221A1

公开(公告)日：2009-04-23

申请号：US11576096

申请日：2005-09-28

Applicant: Mohammad Salman ,  Pakala Kumara Savithru Sarma ,  Arani Pal ,  Anita Chugh ,  Suman Gupta ,  Venkata P. Palle ,  Naresh Kumar ,  Kirandeep Kaur

Inventor： Mohammad Salman ,  Pakala Kumara Savithru Sarma ,  Arani Pal ,  Anita Chugh ,  Suman Gupta ,  Venkata P. Palle ,  Naresh Kumar ,  Kirandeep Kaur

IPC: A61K31/55 ,  C07D223/14 ,  C07D405/12 ,  A61P11/00 ,  A61P1/00

CPC classification number: C07D401/12 ,  C07D221/24 ,  C07D405/06 ,  C07D405/12 ,  C07D409/12

Abstract: This present invention generally relates to muscarinic receptor antagonists of Formula (I), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the prepration of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.

Abstract translation: 本发明一般涉及式（I）的毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病。 本发明还涉及所述化合物的制备方法，包含所公开的化合物的药物组合物，以及通过毒蕈碱受体介导的疾病的治疗方法。

公开(公告)号：US20090099363A1

公开(公告)日：2009-04-16

申请号：US12298409

申请日：2007-04-25

Applicant: Saxena Rahul ,  Verma Naresh Kumar ,  Srinivasan Chidambaram Venkateswaran ,  Wadhwa Lalit

Inventor： Saxena Rahul ,  Verma Naresh Kumar ,  Srinivasan Chidambaram Venkateswaran ,  Wadhwa Lalit

IPC: C07D495/04

CPC classification number: C07D495/04

Abstract: The present invention relates to a novel process for the preparation of polymorphic forms of clopidogrel hydrogen sulfate, namely methyl(+)-(S)-α-(o-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate hydrogen sulfate of formula (I). Particularly the present invention relates to the process for the preparation of form (I) and amorphous clopidogrel hydrogen sulfate.

Abstract translation: 本发明涉及一种制备氯吡格雷硫酸氢盐多形态的新方法，即（+） - （S）-α-（邻氯苯基）-6,7-二氢噻吩并[3,2-c]吡啶 -5（4H） - 乙酸乙酯硫酸氢盐。 特别地，本发明涉及制备形式（I）和无定形氯吡格雷硫酸氢盐的方法。

公开(公告)号：US07514105B2

公开(公告)日：2009-04-07

申请号：US11360653

申请日：2006-02-23

Applicant: Ghulam Nabi Qazi ,  Kasturi Lal Bedi ,  Rakesh Kamal Johri ,  Manoj Kumar Tikoo ,  Ashok Kumar Tikoo ,  Subhash Chander Sharma ,  Sheikh Tasaduq Abdullah ,  Om Parkash Suri ,  Bishan Datt Gupta ,  Krishan Avtar Suri ,  Naresh Kumar Satti ,  Ravi Kant Khajuria ,  Surjit Singh ,  Anamika Khajuria ,  Bal Krishan Kapahi

Inventor： Ghulam Nabi Qazi ,  Kasturi Lal Bedi ,  Rakesh Kamal Johri ,  Manoj Kumar Tikoo ,  Ashok Kumar Tikoo ,  Subhash Chander Sharma ,  Sheikh Tasaduq Abdullah ,  Om Parkash Suri ,  Bishan Datt Gupta ,  Krishan Avtar Suri ,  Naresh Kumar Satti ,  Ravi Kant Khajuria ,  Surjit Singh ,  Anamika Khajuria ,  Bal Krishan Kapahi

IPC: A61K36/00 ,  A61K36/752

CPC classification number: A61K45/06 ,  A23L33/105 ,  A23L33/15 ,  A23L33/16 ,  A23L33/175 ,  A61K31/43 ,  A61K31/4453 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/545 ,  A61K31/704 ,  A61K31/7048 ,  A61K33/04 ,  A61K36/185 ,  A61K36/19 ,  A61K36/23 ,  A61K36/28 ,  A61K36/47 ,  A61K36/59 ,  A61K36/67 ,  A61K36/75 ,  A61K36/80 ,  A61K36/81 ,  A61K36/8965 ,  A61K2300/00

Abstract: The present invention relates to a bioenhancing/bioavailability-facilitating composition comprising: an effective amount of an extract and/or at least one bioactive fraction from Cuminum cyminum; one or more additive selected from drugs, nutrients, vitamins, nutraceuticals, herbal drugs/products, micro nutrients, antioxidants along with pharmaceuticaly acceptable additives/excipient, and optionally, an effective amount of piperine or extract/fraction of piper nigrum or piper longum; and a process for the preparation of such extracts and active fractions from plant Cuminum cyminum.

Abstract translation: 本发明涉及生物增强/生物利用度促进组合物，其包含：有效量的来自孜然的提取物和/或至少一种生物活性级分; 一种或多种选自药物，营养素，维生素，营养品，草药/产品，微量营养素，抗氧化剂以及药用可接受的添加剂/赋形剂的添加剂，以及任选的有效量的胡椒碱或胡椒或胡椒的提取物/级分; 以及从植物孜然中制备这些提取物和活性级分的方法。

公开(公告)号：US20080270622A1

公开(公告)日：2008-10-30

申请号：US12058125

申请日：2008-03-28

Applicant: Naresh Kumar Gupta ,  Rajat Maheshwari ,  Vincent Charlier ,  Gerrit Vermeire

Inventor： Naresh Kumar Gupta ,  Rajat Maheshwari ,  Vincent Charlier ,  Gerrit Vermeire

IPC: G06F15/16

CPC classification number: H04L69/32 ,  H04L69/12 ,  H04W52/0258 ,  H04W76/10 ,  Y02D70/144

Abstract: The present invention discloses a system and a methodology for enhancing performance during wireless communications by reducing system latency, MIPS requirements and power consumption. The present invention discloses a system and method of wireless data communication in which part of upper layer stack processing is performed on a controller to relieve a host processor of some data intensive operations. After the initial connection establishment phase in which the controller retrieves certain information required for data transmission and stores the same locally, the data source provides data directly to the controller without routing the data through the host. The host is relieved of the data processing that needs to be done while the data is being transferred. Hence, the overall latency of the system is improved because of the optimal routing of data traffic. The host can even go to lower power modes while the controller is performing the data operations on behalf of the upper layer stack thereby saving power consumption of the overall system.

Abstract translation: 本发明公开了一种通过减少系统延迟，MIPS要求和功耗来增强无线通信期间的性能的系统和方法。 本发明公开了一种无线数据通信的系统和方法，其中在控制器上执行上层堆栈处理的一部分以减轻主机处理器的某些数据密集型操作。 在控制器检索数据传输所需的某些信息的初始连接建立阶段之后，数据源将数据直接提供给控制器，而不通过主机路由数据。 主机在数据传输时需要完成数据处理。 因此，由于数据流量的最佳路由，系统的整体延迟得到改善。 当控制器代表上层堆栈执行数据操作时，主机甚至可以降低功耗模式，从而节省整个系统的功耗。

公开(公告)号：US07378535B2

公开(公告)日：2008-05-27

申请号：US11414552

申请日：2006-05-01

Applicant: Roger Read ,  Naresh Kumar

Inventor： Roger Read ,  Naresh Kumar

IPC: C07D307/58

CPC classification number: C08F20/00 ,  A01N43/08 ,  C07D307/58 ,  C08F24/00

Abstract: The present invention relates to the side chain functionalization of fimbrolides (halogenated 3-alkyl-5-methylene-2(5H)-furanones) and their synthetic analogues, that yields fimbrolides substituted with a halogen, an oxygen or a nitrogen functionality in the alkyl chain, especially fimbrolide alcohols, carboxylate and sulfinate and sulfonate esters, ethers, aldehydes, ketones, acids, amides, nitro derivatives, hydrophobic, hydrophilic and fluorophilic alkyl derivatives and polymers.

Abstract translation: 本发明涉及福滨洛尔（卤代3-烷基-5-亚甲基-2（5H） - 呋喃酮）及其合成类似物的侧链官能化，其产生在烷基中被卤素，氧或氮官能团取代的菲莫拉林 链，特别是福美罗瑞醇，羧酸盐和亚磺酸盐和磺酸酯，醚，醛，酮，酸，酰胺，硝基衍生物，疏水性，亲水和氟化烷基衍生物和聚合物。